| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 2
| Issue : 2 | Page : 32-37 |
|
|
Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges
Sweety Sharma1, Bhawna Sharma2
1 Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India
2 Department of Nursing, Rajkumari Amrit Kaur College of Nursing, Delhi, India
Correspondence Address:
Dr. Sweety Sharma
Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jphpc.jphpc_8_21
|
|
|
Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type ATTR. Previously, no treatment is available, due to which liver transplantation, multi-organ transplantation, and symptomatic treatment were the only therapies at that time. Approval of Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules in 2019, acts like a kick in the research fields due to which other therapeutics are now emerging. Several clinical trials are going on to evaluate the efficacy of different drugs in ATTR-CM. Most of the clinical trials demonstrated positive outcomes which leads to further evaluation for confirmation. In this review treatment pipeline, ongoing clinical trials and challenges related to ATTR-CM are described.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
